Showing 1271-1280 of 3001 results for "".
- Washout Period Following Dimethyl Fumarate Treatment Cessation Associated with MS Disease Activity and Relapsehttps://practicalneurology.com/news/washout-period-duration-following-dimethyl-fumarate-treatment-cessation-associated-with-ms-disease-activity-and-relapse/2470484/According to results presented at the 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), disease activity was significantly associated with the duration of the interval between cessation of dimethyl fumarate (DMF) treatment and the initiation of an alternative disease-mod
- One-Year Data from OCARINA II Show Suppression of Relapses/Lesions in MS with Subcutaneous Ocrevus Treatmenthttps://practicalneurology.com/news/one-year-data-from-ocarina-ii-show-suppression-of-relapseslesions-in-ms-with-subcutaneous-ocrevus-treatment/2470456/Data from the OCARINA II study (NCT05232825) presented at the American Academy of Neurology (AAN) 2024 Annual Meeting showed that subcutaneous (SC) injection of Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) resulted in near-complete suppression of clinical relapses and brain lesions i
- Prognostic Value of Serum NfL for Predicting Lesion Formation in MS Affirmed by ASCLEPIOS I/IIhttps://practicalneurology.com/news/prognostic-value-of-serum-nfl-for-predicting-lesion-formation-in-ms-affirmed-by-asclepios-iii/2470447/People with relapsing multiple sclerosis (RMS) who had higher 3- and 12-month on-treatment serum neurofilament light chain (sNfL) levels were found to have higher annualized rates of new or emerging T2 (neT2) lesion formation, according to findings from the phase 3 ASCLEPIOS I/II clinical trials
- Investigational Small Molecule Therapy for Progressive MS Associated with Reduced Serum NfL Levels Compared with Placebohttps://practicalneurology.com/news/vidofludimus-calcium-reduces-serum-nfl-levels-compared-with-placebo-in-those-with-progressive-ms/2470416/According to interim analysis of the CALLIPER clinical trial (NCT05054140), people with progressive multiple sclerosis (PMS) subtypes who were treated with VidoCa (vidofludimus calcium; Immunic, New York, NY) as an oral tablet for 24 weeks showed a significant reduction in serum neurofilament lig
- Data from Danish MS Registry Study Provide Patterns and Predictors for Conversion from RRMS to SPMShttps://practicalneurology.com/news/data-from-danish-ms-registry-study-provide-patterns-and-predictors-for-conversion-from-rrms-to-spms/2470309/Researchers analyzing data from the Danish Multiple Sclerosis Registry revealed patterns and predictors for conversion from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SMPS). In all, 21.8% of people with relapsing-remitting multiple sclerosis (RRMS)
- Five-Year Data from ALITHIOS Study on MS Disability Presented at AAN 2023https://practicalneurology.com/news/five-year-data-from-alithios-study-on-ms-disability-presented-at-aan-2023/2470163/According to long-term results of a study presented at the Americ
- Next Generation DHODH Inhibitor Helps Delay Disability in Those with Relapsing-Remitting MShttps://practicalneurology.com/news/next-generation-dhodh-inhibitor-helps-delay-disability-in-those-with-relapsing-remitting-ms/2470124/New clinical trial data suggest that vidofludimus calcium therapy (VidoCa; Immunic, New York, NY) for r
- FDA Removes Category C Warning of Possible Risk in Pregnancy and Breast Feeding for MS Treatment Interferon Beta-1ahttps://practicalneurology.com/news/fda-removes-category-c-warning-of-possible-risk-in-pregnancy-and-breast-feeding-for-ms-treatment-interferon-beta-1a/2469280/The Food and Drug Administration (FDA) has removed the category C warning from the package insert for interferon beta-1a (Rebif; EMD Serono, Rockland, MA). The change is based on the revised Pregnancy and Lactation Labeling Rule (PLLR) and new safety data that the FDA also approved for inclu
- High-Dose Biotin Did Not Improve Disability for Individuals With Active Secondary Progressive MS in Phase 3 Trialhttps://practicalneurology.com/news/high-dose-biotin-did-not-improve-disability-for-individuals-with-active-secondary-progressive-ms-in-phase-3-trial/2469189/The second pivotal phase 3 trial (SPI2) (NCT02936037) of investigational high-dose biotin (MD1003, MedDay Pharmaceuticals, Boston, MA) did not improve disability for individuals with active secondary p
- FDA Approves Cladribine Tablets—First and Only Short-Course Treatment for Relapsing-Remitting MShttps://practicalneurology.com/news/fda-approves-cladribine-tabletsfirst-and-only-short-course-treatment-for-relapsing-remitting-ms/2468787/The Food and Drug Administration (FDA) has approved cladribine tablets (Mavenclad; EMD Serono, Rockland, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS). Cladribine has a dosing schedule tha